Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Pagel, JM; Othus, M; Garcia-Manero, G; Fang, M; Radich, JP; Rizzieri, DA; Marcucci, G; Strickland, SA; Litzow, M; Savoie, ML; Spellman, SR; Confer, DL; Chell, J; Brown, M; Medeiros, BC; Sekeres, MA; Lin, TL; Uy, GL; Powell, BL; Kolitz, JE; Larson, RA; Stone, RM; Claxton, DF; Essell, J; Luger, S; Mohan, SR; Moseley, A; Erba, HP; Appelbaum, FR

Published Date

  • December 2, 2016

Published In

Volume / Issue

  • 128 / 22

Published By


  • 6

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Conference Location

  • San Diego, CA

Conference Start Date

  • December 3, 2016

Conference End Date

  • December 6, 2016